Generated by AI
SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies for central nervous system disorders and related conditions. Its current pipeline includes drug candidates aimed at Tourette syndrome, Alzheimer’s disease and agitation, autism spectrum disorder, status epilepticus, obstructive sleep apnea, and chronic pain. The company’s core programs are built around proprietary formulations that combine cannabinoid compounds with palmitoylethanolamide, supporting both clinical and preclinical development efforts. SciSparc also operates commercial activities through sales of hemp seed oil-based and other hemp-derived consumer products. Based in Tel Aviv, Israel, SciSparc participates in the broader specialty pharmaceutical market by advancing targeted therapies and complementing its research pipeline with product sales and development collaborations.
WebsiteTower A
Tel Aviv-Yafo, 6971916
Israel
The latest articles about SPRC.
Summary of Oct 27's posts. Generated by AI.
Summary of Oct 27's posts. Generated by AI.
Summary of Oct 26's posts. Generated by AI.
Summary of Oct 27's posts. Generated by AI.
Investors talking about SPRC also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.